Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| HVCN1 | Q96D96 | Voltage-gated hydrogen channel 1 (Hydrogen voltage-gated channel 1) (HV1) (Voltage sensor domain-only protein) | Predicted intracellular proteinsPredicted membrane proteinsTransporters | 4 | Fusion and delivery mediationImmune mediationMetabolism mediation | 0.38 | ||||
| HYAS2 | Q92819 | Hyaluronan synthase 2 (EC 2.4.1.212) (Hyaluronate synthase 2) (Hyaluronic acid synthase 2) (HA synthase 2) | 7 | Adhesion and uptake mediationFusion and delivery mediationMetabolism mediation | 0.38 | |||||
| ITA11 | Q9UKX5 | Integrin alpha-11 | Predicted membrane proteinsTransporters | 1 | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 0.38 | ||||
| ITA2 | P17301 | Integrin alpha-2 (CD49 antigen-like family member B) (Collagen receptor) (Platelet membrane glycoprotein Ia) (GPIa) (VLA-2 subunit alpha) (CD antigen CD49b) | Cancer-related genesCD markersHuman disease related genes | 1 | Colorectal cancerSolid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 0.38 | |||
| KCMA1 | Q12791 | Calcium-activated potassium channel subunit alpha-1 (BK channel) (BKCA alpha) (Calcium-activated potassium channel, subfamily M subunit alpha-1) (K(VCA)alpha) (KCa1.1) (Maxi K channel) (MaxiK) (Slo-alpha) (Slo1) (Slowpoke homolog) (Slo homolog) (hSlo) | Disease related genesFDA approved drug targetsHuman disease related genes | 7 | AsthmaFunctional bladder disorder | Clinical-translation mediationFusion and delivery mediationImmune mediation | 0.38 | |||
| LAT2 | Q9UHI5 | Large neutral amino acids transporter small subunit 2 (L-type amino acid transporter 2) (hLAT2) (Solute carrier family 7 member 8) | Metabolic proteinsPredicted membrane proteinsTransporters | 12 | Fusion and delivery mediationImmune mediation | 0.38 | ||||
| LAT4 | Q8N370 | Large neutral amino acids transporter small subunit 4 (L-type amino acid transporter 4) (Solute carrier family 43 member 2) | Metabolic proteinsPredicted membrane proteinsTransporters | 12 | Fusion and delivery mediation | 0.38 | ||||
| LRP6 | O75581 | Low-density lipoprotein receptor-related protein 6 (LRP-6) | Cancer-related genesDisease related genesHuman disease related genes | 1 | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 0.38 | ||||
| LRP8 | Q14114 | Low-density lipoprotein receptor-related protein 8 (LRP-8) (Apolipoprotein E receptor 2) | Disease related genesHuman disease related genesPredicted intracellular proteins | 1 | Fusion and delivery mediationImmune mediationMetabolism mediation | 0.38 | ||||
| MAL2 | Q969L2 | Protein MAL2 | Predicted membrane proteins | 4 | Fusion and delivery mediation | 0.38 | ||||
| MGA | O43451 | Maltase-glucoamylase (Alpha-1,4-glucosidase) (EC 3.2.1.20) | EnzymesFDA approved drug targetsMetabolic proteins | 1 | Acute diabete complicationBlood chemistry clinical symptonCardiovascular disease | Clinical-translation mediationFusion and delivery mediationImmune mediation | 0.38 | |||
| MRP8 | Q96J66 | ATP-binding cassette sub-family C member 11 (EC 7.6.2.2) (EC 7.6.2.3) (Multidrug resistance-associated protein 8) | 12 | Clinical-translation mediationFusion and delivery mediation | 0.38 | |||||
| MUC13 | Q9H3R2 | Mucin-13 (MUC-13) (Down-regulated in colon cancer 1) | Predicted membrane proteinsPredicted secreted proteins | 1 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 0.38 | ||||
| MUC17 | Q685J3 | Mucin-17 (MUC-17) (Small intestinal mucin-3) (MUC-3) | Cancer-related genesPredicted membrane proteins | 1 | Oesophagogastric junction cancerStomach cancer | Clinical-translation mediationFusion and delivery mediationImmune mediation | 0.38 | |||
| NPCL1 | Q9UHC9 | NPC1-like intracellular cholesterol transporter 1 (NPC1L1) (Niemann-Pick C1-like protein 1) | FDA approved drug targetsMetabolic proteinsPredicted membrane proteins | 13 | Hyper-lipoproteinaemia | Clinical-translation mediationFusion and delivery mediation | 0.38 | |||
| ORAI1 | Q96D31 | Calcium release-activated calcium channel protein 1 (Protein orai-1) (Transmembrane protein 142A) | Disease related genesHuman disease related genesPotential drug targets | 4 | Fusion and delivery mediationImmune mediationReceptor-signaling mediation | 0.38 | ||||
| OXYR | P30559 | Oxytocin receptor (OT-R) | 7 | Fusion and delivery mediationMetabolism mediationReceptor-signaling mediation | 0.38 | |||||
| PKD1 | P98161 | Polycystin-1 (PC1) (Autosomal dominant polycystic kidney disease 1 protein) | Disease related genesHuman disease related genesPlasma proteins | 11 | Adhesion and uptake mediationFusion and delivery mediationMetabolism mediation | 0.38 | ||||
| RHCG | Q9UBD6 | Ammonium transporter Rh type C (Rh glycoprotein kidney) (Rhesus blood group family type C glycoprotein) (Rh family type C glycoprotein) (Rh type C glycoprotein) (Tumor-related protein DRC2) | Metabolic proteinsPredicted membrane proteinsTransporters | 12 | Fusion and delivery mediation | 0.38 | ||||
| S12A3 | P55017 | Solute carrier family 12 member 3 (Na-Cl cotransporter) (NCC) (Na-Cl symporter) (Thiazide-sensitive sodium-chloride cotransporter) | Disease related genesFDA approved drug targetsHuman disease related genes | 12 | Essential hypertensionHypertensionOedema | Clinical-translation mediationFusion and delivery mediation | 0.38 | |||
| S13A2 | Q13183 | Solute carrier family 13 member 2 (Na(+)/dicarboxylate cotransporter 1) (NaDC-1) (Renal sodium/dicarboxylate cotransporter) | Metabolic proteinsPredicted membrane proteinsTransporters | 12 | Fusion and delivery mediation | 0.38 | ||||
| S20A2 | Q08357 | Sodium-dependent phosphate transporter 2 (Gibbon ape leukemia virus receptor 2) (GLVR-2) (Phosphate transporter 2) (PiT-2) (Pit2) (hPit2) (Solute carrier family 20 member 2) | Disease related genesHuman disease related genesMetabolic proteins | 12 | Clinical-translation mediationFusion and delivery mediation | 0.38 | ||||
| S22A2 | O15244 | Solute carrier family 22 member 2 (Organic cation transporter 2) (hOCT2) | Metabolic proteinsPredicted membrane proteinsTransporters | 12 | Clinical-translation mediationFusion and delivery mediation | 0.38 | ||||
| S22A6 | Q4U2R8 | Solute carrier family 22 member 6 (Organic anion transporter 1) (hOAT1) (PAH transporter) (hPAHT) (Renal organic anion transporter 1) (hROAT1) | FDA approved drug targetsMetabolic proteinsPredicted membrane proteins | 12 | Clinical-translation mediationFusion and delivery mediation | 0.38 | ||||
| S22A8 | Q8TCC7 | Organic anion transporter 3 (hOAT3) (Organic anion/dicarboxylate exchanger) (Solute carrier family 22 member 8) | FDA approved drug targetsMetabolic proteinsPredicted membrane proteins | 11 | GoutHerpes simplex infectionInborn purine/pyrimidine/nucleotide metabolism error | Clinical-translation mediationFusion and delivery mediation | 0.38 |